BFC
RKDA icon

Bedel Financial Consulting’s Arcadia Biosciences RKDA Stock Holding History

Bedel Financial Consulting’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46
Closed -$3K – 734
2022
Q1 		$3K Hold
46
– – ﹤0.01% 844
2021
Q4 		$2K Hold
46
– – ﹤0.01% 904
2021
Q3 		$4K Hold
46
– – ﹤0.01% 815
2021
Q2 		$5K Buy
+46
New +$5.01K ﹤0.01% 779

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Bedel Financial Consulting's RKDA Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Arcadia Biosciences (RKDA) in Q2 2022, closing a stake of 46 shares — an estimated $3K sold.

Bedel Financial Consulting first reported a position in RKDA in Q2 2021 and held it in 4 quarters. The position peaked at $5K in Q2 2021. 22 funds tracked by Wall St. Rank hold RKDA as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Arcadia Biosciences position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 46 Arcadia Biosciences shares in Q2 2022, an estimated $3K.
  • Bedel Financial Consulting first reported a position in Arcadia Biosciences in Q2 2021 and held it in 4 quarters.
  • Bedel Financial Consulting's Arcadia Biosciences position peaked at $5K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.